AstraZeneca PLC [NASDAQ: AZN] traded at a high on 06/22/22, posting a 1.15 gain after which it closed the day’ session at $63.55. The company report on June 21, 2022 that PROpel Phase III Trial Positive Results of LYNPARZA® (olaparib) Plus Abiraterone in 1st-line Metastatic Castration-resistant Prostate Cancer Published in New England Journal of Medicine Evidence.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free.
Combination reduced risk of disease progression by 34% vs. standard-of-care in patients irrespective of homologous recombination repair gene mutation status.
Results from the PROpel Phase III trial showed that LYNPARZA® (olaparib), jointly developed and commercialized by AstraZeneca and Merck & Co., Inc., known as MSD outside the US and Canada, in combination with abiraterone significantly improved radiographic progression-free survival (rPFS) versus abiraterone alone as a 1st-line treatment for patients with metastatic castration-resistant prostate cancer (mCRPC) with or without homologous recombination repair (HRR) gene mutations. The results, showing the combination reduced the risk of disease progression or death by 34% versus abiraterone alone (based on a hazard ratio [HR] of 0.66; 95% confidence interval [CI] 0.54-0.81; p<0.0001), are now published in the New England Journal of Medicine (NEJM) Evidence.1. The results of the trading session contributed to over 5298393 shares changing hands. Over the past one week, the price volatility of AstraZeneca PLC stands at 1.85% while the volatility over the past one month is 1.73%. The market cap for AZN stock reached $191.58 billion, with 3.10 billion shares outstanding and 2.99 billion shares in the current float. Compared to the average trading volume of 7.14M shares, AZN reached a trading volume of 5298393 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about AstraZeneca PLC [AZN]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for AZN shares is $71.80 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on AZN stock is a recommendation set at 2.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
UBS have made an estimate for AstraZeneca PLC shares, keeping their opinion on the stock as Neutral, with their previous recommendation back on June 14, 2022. The new note on the price target was released on February 11, 2022, representing the official price target for AstraZeneca PLC stock.
The Average True Range (ATR) for AstraZeneca PLC is set at 1.49, with the Price to Sales ratio for AZN stock in the period of the last 12 months amounting to 4.62. The Price to Book ratio for the last quarter was 5.41, with the Price to Cash per share for the same quarter was set at 1.93. Price to Free Cash Flow for AZN in the course of the last twelve months was 105.67 with Quick ratio for the last quarter at 0.70.
How has AZN stock performed recently?
AstraZeneca PLC [AZN] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 7.24. With this latest performance, AZN shares dropped by -4.02% in over the last four-week period, additionally plugging by 12.36% over the last 6 months – not to mention a rise of 9.78% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for AZN stock in for the last two-week period is set at 49.90, with the RSI for the last a single of trading hit 53.58, and the three-weeks RSI is set at 48.99 for AstraZeneca PLC [AZN]. The present Moving Average for the last 50 days of trading for this stock 65.18, while it was recorded at 61.78 for the last single week of trading, and 60.97 for the last 200 days.
AstraZeneca PLC [AZN]: Deeper insight into the fundamentals
Operating Margin for any stock indicates how profitable investing would be, and AstraZeneca PLC [AZN] shares currently have an operating margin of +7.57 and a Gross Margin at +60.90. AstraZeneca PLC’s Net Margin is presently recorded at +0.30.
Return on Total Capital for AZN is now 5.33, given the latest momentum, and Return on Invested Capital for the company is 0.22. Return on Equity for this stock inclined to 0.40, with Return on Assets sitting at 0.13. When it comes to the capital structure of this company, AstraZeneca PLC [AZN] has a Total Debt to Total Equity ratio set at 78.39. Additionally, AZN Total Debt to Total Capital is recorded at 43.94, with Total Debt to Total Assets ending up at 29.21. Long-Term Debt to Equity for the company is recorded at 73.57, with the Long-Term Debt to Total Capital now at 41.24.
Reflecting on the efficiency of the workforce at the company, AstraZeneca PLC [AZN] managed to generate an average of $980 per employee. Receivables Turnover for the company is 5.18 with a Total Asset Turnover recorded at a value of 0.43.AstraZeneca PLC’s liquidity data is similarly interesting compelling, with a Quick Ratio of 0.70 and a Current Ratio set at 1.00.
Earnings analysis for AstraZeneca PLC [AZN]
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for AZN. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for AstraZeneca PLC go to 15.40%.
Insider trade positions for AstraZeneca PLC [AZN]
There are presently around $32,621 million, or 17.80% of AZN stock, in the hands of institutional investors. The top three institutional holders of AZN stocks are: PRICE T ROWE ASSOCIATES INC /MD/ with ownership of 94,229,869, which is approximately 4.885% of the company’s market cap and around 0.50% of the total institutional ownership; WELLINGTON MANAGEMENT GROUP LLP, holding 46,691,035 shares of the stock with an approximate value of $2.93 billion in AZN stocks shares; and PRIMECAP MANAGEMENT CO/CA/, currently with $2.91 billion in AZN stock with ownership of nearly -0.798% of the company’s market capitalization.
Positions in AstraZeneca PLC stocks held by institutional investors increased at the end of April and at the time of the April reporting period, where 456 institutional holders increased their position in AstraZeneca PLC [NASDAQ:AZN] by around 50,794,615 shares. Additionally, 393 investors decreased positions by around 36,926,631 shares, while 213 investors held positions by with 431,471,671 shares. The mentioned changes placed institutional holdings at 519,192,917 shares, according to the latest SEC report filing. AZN stock had 115 new institutional investments in for a total of 4,953,985 shares, while 87 institutional investors sold positions of 5,516,415 shares during the same period.